PMID- 22322482
OWN - NLM
STAT- MEDLINE
DCOM- 20120815
LR  - 20211021
IS  - 1420-908X (Electronic)
IS  - 1023-3830 (Linking)
VI  - 61
IP  - 5
DP  - 2012 May
TI  - Effects of 1,25-(OH)(2)D (3) on the expressions of vitamin D receptor, STAT5 and 
      cytoskeletal rearrangement in human monocytes incubated with sera from type 2 
      diabetes patients and diabetic nephropathy patients with uremia.
PG  - 511-20
LID - 10.1007/s00011-012-0441-y [doi]
AB  - OBJECTIVE: To explore the effects of 1,25-(OH)(2)D(3) and lipopolysaccharide 
      (LPS) plus human recombinant interleukin-15 (IL-15) on expression of vitamin D 
      receptor (VDR) and STAT5, and cytoskeletal rearrangement in human monocytes 
      incubated with sera from type 2 diabetes (T2DM) patients and diabetic nephropathy 
      (DN) patients with uremia. MATERIALS AND METHODS: Peripheral sera were isolated 
      from healthy volunteers (control group, T2DM patients and DN uremic non-dialysis 
      patients). After incubation with or without 1,25(OH)(2)D(3), THP-1 monocytes were 
      treated with LPS plus IL-15 prior to the collection of cells and supernatants. 
      VDR mRNA transcription was examined by RT-PCR, whilst THP-1 monocytic VDR, STAT5 
      and p-STAT5 expressions were investigated by Western blotting. Concentrations of 
      IL-6 and monocyte chemoattractant protein-1 (MCP-1) in supernatants were assessed 
      by ELISA. Immunofluorescence and a laser confocal microscopy was used to examine 
      the expression of VDR and cytoskeletal proteins. RESULTS: Compared to the normal 
      control, LPS and IL-15 down-regulate monocytic VDR expression in T2DM patients 
      and DN uremic patients, whilst with cytoskeletal rearrangement, they up-regulate 
      p-STAT5 expression as well as IL-6 and MCP-1 activity. Such effects could be in 
      part blocked by 1,25-(OH)(2)D(3). CONCLUSION: The above results suggest that the 
      anti-inflammatory mechanism of 1,25-(OH)(2)D(3) may be related to cytoskeletal 
      proteins, VDR and STAT5 signaling pathway.
FAU - Yang, Mengxue
AU  - Yang M
AD  - Department of Nephrology, First Affiliated Hospital of ChongQing Medical 
      University, ChongQing, China. yangmengxue02@126.com
FAU - Shen, Zhaonan
AU  - Shen Z
FAU - Chen, Danyan
AU  - Chen D
FAU - Gan, Hua
AU  - Gan H
FAU - Shen, Qing
AU  - Shen Q
FAU - Yang, Bo
AU  - Yang B
FAU - Du, XiaoGang
AU  - Du X
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120210
PL  - Switzerland
TA  - Inflamm Res
JT  - Inflammation research : official journal of the European Histamine Research 
      Society ... [et al.]
JID - 9508160
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Interleukin-15)
RN  - 0 (Interleukin-6)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Receptors, Calcitriol)
RN  - 0 (STAT5 Transcription Factor)
RN  - 0 (STAT5A protein, human)
RN  - 0 (Tumor Suppressor Proteins)
RN  - FXC9231JVH (Calcitriol)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Calcitriol/*pharmacology
MH  - Cells, Cultured
MH  - Chemokine CCL2/biosynthesis
MH  - Cytoskeleton/chemistry/*drug effects
MH  - Diabetes Mellitus, Type 2/*blood
MH  - Diabetic Nephropathies/*blood
MH  - Female
MH  - Humans
MH  - Interleukin-15/pharmacology
MH  - Interleukin-6/biosynthesis
MH  - Lipopolysaccharides/pharmacology
MH  - Male
MH  - Microscopy, Fluorescence
MH  - Middle Aged
MH  - Monocytes/*drug effects/metabolism
MH  - Receptors, Calcitriol/*analysis/genetics
MH  - STAT5 Transcription Factor/*analysis
MH  - Signal Transduction
MH  - Tumor Suppressor Proteins/*analysis
MH  - Uremia/*blood
EDAT- 2012/02/11 06:00
MHDA- 2012/08/16 06:00
CRDT- 2012/02/11 06:00
PHST- 2011/10/03 00:00 [received]
PHST- 2012/01/20 00:00 [accepted]
PHST- 2012/01/05 00:00 [revised]
PHST- 2012/02/11 06:00 [entrez]
PHST- 2012/02/11 06:00 [pubmed]
PHST- 2012/08/16 06:00 [medline]
AID - 10.1007/s00011-012-0441-y [doi]
PST - ppublish
SO  - Inflamm Res. 2012 May;61(5):511-20. doi: 10.1007/s00011-012-0441-y. Epub 2012 Feb 
      10.